ProMIS Neurosciences Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

PMN$3.98-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(expressed in US dollars)


· · Three Months Ended ·
· · March 31, ·
· 2024 · 2023 ·
Cash flows from operating activities
Net loss	$(3,635,088)	$(4,959,431)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	63,584	132,510
Foreign currency exchange gain	—	(4,984)
Change in fair value of warrant liability	14,133	41,665
Depreciation of property and equipment	—	322
Amortization of intangible assets	—	1,233
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(30,328)	(45,966)
Accounts payable	(6,439,544)	4,002,389
Accrued liabilities	(264,204)	(1,729,392)
Net cash used in operating activities	(10,291,447)	(2,561,654)
Cash flows from financing activities
Proceeds from issuance of Common Shares from ATM Offering, net of issuance costs	190,274	—
Net cash provided by financing activities	190,274	—
Effect of exchange rates on cash	—	17,659
Net decrease in cash	(10,101,173)	(2,543,995)

Cash at beginning of year	12,598,146	5,875,796
Cash at end of period	$2,496,973	$3,331,801

Noncash financing activities
Increase in share-based compensation liability on CAD denominated share options decreasing additional paid-in-capital	$294,967	$—

Supplemental disclosure of cash flow information
Cash paid for interest	$76,775	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.